The estimated Net Worth of Richard J Kim is at least 2.63 百万$ dollars as of 2 October 2017. Mr. Kim owns over 48 units of Intercept Pharmaceuticals Inc stock worth over 212,895$ and over the last 7 years he sold ICPT stock worth over 20,322$. In addition, he makes 2,399,330$ as President、 U.S. Commercial & Strategic Marketing at Intercept Pharmaceuticals Inc.
Sign up
Mr. Kim ICPT stock SEC Form 4 insiders trading
Richard has made over 3 trades of the Intercept Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 48 units of ICPT stock worth 2,789$ on 2 October 2017.
The largest trade he's ever made was selling 89 units of Intercept Pharmaceuticals Inc stock on 14 July 2017 worth over 11,449$. On average, Richard trades about 8 units every 4 days since 2017. As of 2 October 2017 he still owns at least 11,205 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kim stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Kim biography
Richard Kim serves as President, U.S. Commercial & Strategic Marketing of the Company. He has over 20 years of commercial, marketing and managerial experience in the biopharmaceutical industry in the United States and abroad. Prior to joining the Company, Mr. Kim worked at Bristol-Myers Squibb starting in 2004, where he most recently served as General Manager, Hepatitis C Worldwide Commercialization. Prior to that, Mr. Kim held a number of roles of increasing responsibility at Bristol-Myers Squibb, including Vice President, SPRYCEL Brand Lead, Oncology Global Marketing; Vice President, U.S. In-Line Oncology and Global Marketing for Necitumumab; and Vice President, East Area Sales, Cardiovascular and Metabolics. Prior to holding these positions, Mr. Kim held a range of senior positions in the United States, Canada and Australia at Schering-Plough, which was acquired by Merck & Co., Inc. Mr. Kim earned his bachelor’s degree in chemistry from the University of Alberta.
What is the salary of Richard Kim?
As the President、 U.S. Commercial & Strategic Marketing of Intercept Pharmaceuticals Inc, the total compensation of Richard Kim at Intercept Pharmaceuticals Inc is 2,399,330$. There are 3 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of 6,615,780$.
How old is Richard Kim?
Richard Kim is 51, he's been the President、 U.S. Commercial & Strategic Marketing of Intercept Pharmaceuticals Inc since 2019. There are 16 older and 5 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
What's Richard Kim's mailing address?
Richard's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Insiders trading at Intercept Pharmaceuticals Inc
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over 1,530,243,701$ worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth 77,118,364$ . The most active insiders traders include Srinivas Akkaraju、Jonathan Silverstein、Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of 1,114,673$. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth 5,017,290$.
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
What does Intercept Pharmaceuticals Inc's logo look like?
Complete history of Mr. Kim stock trades at Avadel Pharmaceuticals plc、Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc executives and stock owners
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Mark Pruzanski,
President, Chief Executive Officer, Director -
Jerome Durso,
Chief Operating Officer -
Ryan Sullivan,
General Counsel, Secretary -
Richard Kim,
President, U.S. Commercial & Strategic Marketing -
Sandip Kapadia,
Chief Financial Officer, Treasurer -
Gail Cawkwell,
Senior Vice President - Medical Affairs, Safety & Pharmacovigilance -
Lisa Bright,
President, International -
David Ford,
Chief Human Resource Officer -
Dr. Mark Pruzanski M.D.,
Founder, Advisor & Director -
Jerome B. Durso,
Pres, CEO & Director -
Paolo Fundaro,
Independent Chairman of the Board -
Gino Santini,
Lead Independent Director -
Glenn Sblendorio,
Independent Director -
Daniel Welch,
Independent Director -
Daniel Bradbury,
Independent Director -
Luca Benatti,
Independent Director -
Nancy Miller-Rich,
Independent Director -
Keith Gottesdiener,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Jason Campagna,
Chief Medical Officer -
Christian Weyer,
Executive Vice President - Research & Development -
Linda M. Richardson,
Exec. VP & Chief Commercial Officer -
Jared M. Freedberg J.D.,
Gen. Counsel -
Lisa M. DeFrancesco,
Sr. VP of Corp. Affairs & Investor Relations -
Rocco Venezia,
Chief Accounting Officer & Treasurer -
Bryan Ball,
Chief Quality Officer & Sr. VP of Operations -
Andrew Saik,
Chief Financial Officer -
Barbara Gayle Duncan,
Chief Financial Officer -
Rachel Mc Minn,
Chief Strategy Officer -
David Shapiro,
Chief Medical Officer -
Linda M Richardson,
EVP & Chief Commercial Officer -
S.P.A. Genextra,
-
M Michelle Berrey,
President, R&D and CMO -
Daniel Paul Regan,
Chief Commerical Officer -
Jonathan Silverstein,
Director -
Advisors Llc Orbi Med Capit...,
-
Lorenzo Tallarigo,
Director -
Klaus R Dr Veitinger,
Director -
Sanj K Patel,
Director -
Luciano Adorini,
Chief Scientific Officer -
Nicole Williams,
Director -
Francesco Micheli,
-
Bryan Ball,
Chief Qual. Officer & SVP Ops. -
Rocco Venezia,
Chief Accounting Officer -
Dagmar Rosa Bjorkeson,
Director -
Lisa De Francesco,
SVP, IR & Corp. Affairs -
Jared Freedberg,
General Counsel